DRUG NEWS

$3.95
Nursing2014
December 2012 
Volume 42  Number 12
Pages 8 - 9
 
  PDF Version Available!

ABSTRACT
The FDA recently approved adalimumab (Humira) for treatment of moderate-to-severe ulcerative colitis in adults when treatment with other immunosuppressants has failed. Adalimumab had been approved previously to treat various other disorders, including rheumatoid arthritis, plaque psoriasis, and Crohn disease. Classified as a tumor necrosis factor blocker, adalimumab blocks the proteins that help spark abnormal inflammatory and immune responses.Adalimumab should be continued only in patients with evidence of clinical remission by the eighth week of therapy. The most common adverse reactions include infections, such as upper respiratory tract infections and sinusitis, injection site reactions, headache, and rash. Adalimumab carries a boxed warning because of the risk of serious infection and malignancy.Source: FDA approves Humira to treat ulcerative colitis. FDA news release. 2012; September 28.After myocardial infarction (MI), beta-blockers are a standard treatment. But do they benefit patients with no recent history of MI? To find out, researchers examined the use of beta-blockers in three groups: stable patients with a remote history of MI, patients with coronary artery disease (CAD) but no history of MI, and patients with only risk factors for CAD. The observational study included 44,708 patients with a follow-up (median) of 44 months. The primary outcome was a composite of cardiovascular death, nonfatal MI, or nonfatal stroke.Event outcomes weren't significantly different in patients taking beta-blockers compared with those not taking beta-blockers. However, risk of the primary outcome was higher for patients taking beta-blockers in the group of patients with CAD risk factors only.Researchers concluded that the use of beta-blockers wasn't associated with a lower risk of composite cardiovascular events in any of the three study groups.Source: Bangalore S, Steg G, Deedwania P, et al. [beta]-blocker use and clinical outcomes in stable outpatients with and without coronary

Purchase Now !

To purchase this item, follow the instructions below. If you’re not already logged in, be sure to enter your login information below to ensure that your item is saved to your File Drawer after you purchase it.

Not a member? Join now for Free!


Cost:$3.95
1) If you're not already logged in, enter your information below to save this item in your File Drawer for future viewing.

User name:


Password


Forgot your user name or password?
2)  If you have a coupon or promotional code, enter it
here.(If not, just click Continue.


Digital Coupon: (optional)

3)  Click Continue to go to the next screen, where
you'll enter your payment details.






jQuery UI Accordion - Default functionality

For life-long learning and continuing professional development, come to Lippincott's NursingCenter.

Nursing Jobs Plus
Featured Jobs
Recommended CE Articles Recommended Nursing Articles

Dogs as Pets, Visitors, Therapists and Assistants
Home Healthcare Nurse, November/December 2014
Free access will expire on January 5, 2015.


Tracheostomy Care
Nursing2014 Critical Care, November 2014
Free access will expire on December 22, 2014.


Effective management of ARDS
The Nurse Practitioner, 13December 2014
Free access will expire on December 22, 2014.


More Recommended Articles

Subscribe to Recommended Articles

Evidence Based Practice Skin Care Network NursingCenter Quick Links What’s Trending Events